To the best our knowledge, this is the first study to demonstrate pretreatment serum albumin levels as an independent predictor of long-term OS (OS ≥ 2 years) in R/M HNSCC patients treated with nivolumab. Here, ALB is linked to head and neck squamous cell carcinoma.